Utilizing Tumor Metabolism in Solid Malignancies

Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Benjamin P. Levy, MD, discusses the mechanism ​of action of telaglenastat in non–small cell lung cancer.

Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.